Nanoparticles Quillaja Saponin DUE-C300 for treatment of solid tumors
| Reference number | |
| Coordinator | MOREINX AB - Moreinx |
| Funding from Vinnova | SEK 50 000 |
| Project duration | January 2015 - March 2015 |
| Status | Completed |
Purpose and goal
The purpose of the planning project was to identify potential collaborator and to visit United Arab Emirates for two groups, New York University Abu Dhabi and Sharjah University. AMMLab-New York University Abu Dhabi was identified as the most suitable partner and together we designed a complete application within the program of VINNMER Marie Curie Industry outgoing. Full application was submitted to Vinnova in March 2015. The aim of this application is to lead a project in the area of G3 Nanoparticles for prostate cancer treatment and to start long-term collaboration with AMMLab.
Results and expected effects
An application for a Marie Curie Industry Outgoing project was completed in the planning project and was submitted to Vinnova. The expected outcome of the project is granted application, a long-term partnership that strengthens MoreinX international position in the field of cancer treatment, and career advancement for Wehelie. Strong opportunities for collaborations between MorienX, AMMLab-NYUAD, Harvard Medical School, and Massachusetts Institute of Technology have already been established during the project-planning phase. A career plan has been established for Wehelie.
Approach and implementation
The project leader visited two groups in the United Arab Emirates for two weeks. The purpose of the planning project was to identify potential collaborator in United Arab Emirates. This has been done through visits and discussions with the two groups and we identified that AMMLab-NYUAD as a collaborator. Together we drafted a full project application and submitted to the Vinnova. Other university visited was not within the frame of VINNMER Marie Curie Industry outgoing program.